On Monday, MaxCyte Inc (NASDAQ: MXCT) opened lower -4.35% from the last session, before settling in for the closing price of $2.3. Price fluctuations for MXCT have ranged from $2.00 to $5.20 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -11.37%. Company’s average yearly earnings per share was noted 8.54% at the time writing. With a float of $97.66 million, this company’s outstanding shares have now reached $106.31 million.
Considering the fact that the conglomerate employs 114 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 78.16%, operating margin of -133.05%, and the pretax margin is -110.92%.
MaxCyte Inc (MXCT) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Medical Devices industry is another important factor to consider. The insider ownership of MaxCyte Inc is 8.14%, while institutional ownership is 74.35%. The most recent insider transaction that took place on Jun 25 ’25, was worth 22,378. Before that another transaction happened on Mar 18 ’25, when Company’s Chief Commercial Officer sold 1,211 for $3.18, making the entire transaction worth $3,850. This insider now owns 59,439 shares in total.
MaxCyte Inc (MXCT) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 8.54% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.79% during the next five years compared to -11.37% drop over the previous five years of trading.
MaxCyte Inc (NASDAQ: MXCT) Trading Performance Indicators
Check out the current performance indicators for MaxCyte Inc (MXCT). In the past quarter, the stock posted a quick ratio of 11.58. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.21.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.40, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.34 in one year’s time.
Technical Analysis of MaxCyte Inc (MXCT)
Compared to the last year’s volume of 0.79 million, its volume of 1.25 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 77.47%.
During the past 100 days, MaxCyte Inc’s (MXCT) raw stochastic average was set at 7.49%, which indicates a significant decrease from 52.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.63% in the past 14 days, which was lower than the 62.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.40, while its 200-day Moving Average is $3.43. Nevertheless, the first resistance level for the watch stands at $2.29 in the near term. At $2.37, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.43. If the price goes on to break the first support level at $2.14, it is likely to go to the next support level at $2.08. Now, if the price goes above the second support level, the third support stands at $2.00.
MaxCyte Inc (NASDAQ: MXCT) Key Stats
There are currently 106,416K shares outstanding in the company with a market cap of 233.90 million. Presently, the company’s annual sales total 38,630 K according to its annual income of -41,060 K. Last quarter, the company’s sales amounted to 10,390 K and its income totaled -10,260 K.
